Neurocrine Biosciences heads into its May 5 Q1 results with a notable and accelerating build in short positions — the most distinctive feature of the current setup.
Short interest has climbed sharply over the past month, rising nearly 29% to reach 5.35% of free float — up from roughly 4.2% at the start of April and 3.6% in late March. The week-on-week increase of almost 19% is particularly striking, with the bulk of new shorts added in a cluster around April 23–24. That kind of concentrated build in the final days before an earnings release is a clear signal that some traders are positioning for disappointment. Despite the added pressure from the short side, borrow conditions remain unusually calm: cost to borrow holds near 0.45%, and availability is ample, meaning the build has not stressed the lending market.
Options positioning, however, tells the opposite story. The put/call ratio has moved sharply lower over the past two weeks, dropping from above 1.5 in early April to just 0.97 — well below its 20-day average of 1.20, and nearly a full standard deviation beneath that mean. That shift points to a meaningful rotation toward calls, with options traders becoming more constructive heading into the print, even as short sellers pile in from the other side. The divergence between these two signals is the defining tension of the setup.
Analysts lean bullish, and recently became more so. Multiple firms raised price targets in early April following what appears to have been a data event or commercial update. Citigroup lifted its target to $242 and Canaccord moved to $200, both maintaining Buy ratings. Morgan Stanley nudged its Equal-Weight target to $185. More recently, Leerink raised its Outperform target to $170, still below the $131.78 current price's implied upside to the mean consensus of $185. That gap — roughly 41% — reflects the Street's continued belief that the stock is undervalued, though the range of targets is wide. The bull case centres on Ingrezza's revenue durability and the potential for the Crenessity launch to build momentum; bears focus on Crenessity's patchy early sales trajectory, rising R&D spend, and the competitive risks that came sharply into focus after the February print — when the stock fell more than 10% on the day and extended losses to nearly 7% over the following week.
The EPS momentum picture adds nuance on the constructive side: forward-year estimate revisions rank in the 95th percentile over 30 days, suggesting analysts have been upgrading their numbers. Yet the earnings surprise factor scores just in the 29th percentile, a reminder that beating consensus has not been a reliable habit. The Q1 print is therefore less a test of Ingrezza's franchise and more a verdict on whether Crenessity is gaining real commercial traction — and whether a stock that has recovered just 3% over the past month can justify the Street's target-price optimism after February's selloff.
See the live data behind this article on ORTEX.
Open NBIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
